Highlights
1 patent
About
Novel RNA-targeting Drugs
1E Therapeutics is a drug-development company creating RNA-targeting therapeutics based on a proprietary drug-design platform. 1E's process has proven able to develop drugs that address chronic life-threatening indications as well as emerging and evolving pathogens. 1E already has lead compounds that address a wide array of indications in oncology, age-related diseases, immunology, anti-microbial resistance, viral infections, and orphan neurological disorders.
Identity
| Name | 1E Therapeutics |
|---|---|
| Slug | 1e-therapeutics |
| Type / kind | startup |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAkMiHidcJDA |
Status
| Status | active |
|---|---|
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | Center District |
| HQ city | Rehovot |
| HQ address | Haim Holtsman Street 7, Rehovot, Israel |
Web & social
| Website | https://1etx.com |
|---|---|
| https://www.linkedin.com/company/72749387 |
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsMolecules
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business models
B2B
Tags
genetic-disorderscancerpharmaceuticalschronic-diseaseimmunologyviral-diseasesoncologypharma-companiesdrug-developmenttherapeuticsinfectious-disease
Funding
| Total raised | $120.0M |
|---|---|
| Current stage | Seed |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}